These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8649850)

  • 41. An in vitro model of posterior capsular opacity: SPARC and TGF-beta2 minimize epithelial-to-mesenchymal transition in lens epithelium.
    Gotoh N; Perdue NR; Matsushima H; Sage EH; Yan Q; Clark JI
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4679-87. PubMed ID: 17898292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
    Modesitt SC; Ramirez P; Zu Z; Bodurka-Bevers D; Gershenson D; Wolf JK
    Clin Cancer Res; 2001 Jun; 7(6):1765-72. PubMed ID: 11410518
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression.
    Bagnoli M; Tomassetti A; Figini M; Flati S; Dolo V; Canevari S; Miotti S
    Oncogene; 2000 Sep; 19(41):4754-63. PubMed ID: 11032026
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice.
    Lin X; Chen X; Wei Y; Zhao J; Fan L; Wen Y; Wu H; Zhao X
    Gynecol Oncol; 2007 Mar; 104(3):540-6. PubMed ID: 17112567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of Zuoguiyin on expression of ovarian VEGF and SPARC in rats during peri-menopausal period].
    Zhao W; Wen H; Zheng H; Sun S; Ni J
    Zhongguo Zhong Yao Za Zhi; 2009 Nov; 34(22):2932-6. PubMed ID: 20209964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer.
    Chen J; Wang M; Xi B; Xue J; He D; Zhang J; Zhao Y
    PLoS One; 2012; 7(8):e42413. PubMed ID: 22879971
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation.
    Karlan BY; Baldwin RL; Cirisano FD; Mamula PW; Jones J; Lagasse LD
    Gynecol Oncol; 1995 Oct; 59(1):67-74. PubMed ID: 7557618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of the ovarian microenvironment on the anti-tumor effect of SPARC on ovarian cancer.
    Greenaway JB; Koehler A; McCulloch CA; Petrik J; Brown TJ; Ringuette MJ
    Biochem Cell Biol; 2012 Feb; 90(1):96-107. PubMed ID: 22003835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.
    Bull Phelps SL; Carbon J; Miller A; Castro-Rivera E; Arnold S; Brekken RA; Lea JS
    Am J Obstet Gynecol; 2009 Feb; 200(2):180.e1-7. PubMed ID: 18992864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host.
    Podhajcer OL; Benedetti LG; Girotti MR; Prada F; Salvatierra E; Llera AS
    Cancer Metastasis Rev; 2008 Dec; 27(4):691-705. PubMed ID: 18542844
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.
    Said N; Motamed K
    Am J Pathol; 2005 Dec; 167(6):1739-52. PubMed ID: 16314484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Integrative genomic analyses of secreted protein acidic and rich in cysteine and its role in cancer prediction.
    Wang B; Chen K; Xu W; Chen D; Tang W; Xia TS
    Mol Med Rep; 2014 Sep; 10(3):1461-8. PubMed ID: 24938427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer.
    Said N; Najwer I; Motamed K
    Am J Pathol; 2007 Mar; 170(3):1054-63. PubMed ID: 17322388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model.
    Noorani L; Stenzel M; Liang R; Pourgholami MH; Morris DL
    J Nanobiotechnology; 2015 Mar; 13():25. PubMed ID: 25890381
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Caenorhabditis elegans homologue of the extracellular calcium binding protein SPARC/osteonectin affects nematode body morphology and mobility.
    Schwarzbauer JE; Spencer CS
    Mol Biol Cell; 1993 Sep; 4(9):941-52. PubMed ID: 8257796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Testican-3: a brain-specific proteoglycan member of the BM-40/SPARC/osteonectin family.
    Hartmann U; Hülsmann H; Seul J; Röll S; Midani H; Breloy I; Hechler D; Müller R; Paulsson M
    J Neurochem; 2013 May; 125(3):399-409. PubMed ID: 23418755
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix.
    Chlenski A; Liu S; Guerrero LJ; Yang Q; Tian Y; Salwen HR; Zage P; Cohn SL
    Int J Cancer; 2006 Jan; 118(2):310-6. PubMed ID: 16052522
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC.
    John B; Naczki C; Patel C; Ghoneum A; Qasem S; Salih Z; Said N
    Oncogene; 2019 May; 38(22):4366-4383. PubMed ID: 30765860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis.
    Nagaraju GP; Dontula R; El-Rayes BF; Lakka SS
    Carcinogenesis; 2014 May; 35(5):967-73. PubMed ID: 24675529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids.
    Chlenski A; Dobratic M; Salwen HR; Applebaum M; Guerrero LJ; Miller R; DeWane G; Solomaha E; Marks JD; Cohn SL
    Oncotarget; 2016 Nov; 7(47):77696-77706. PubMed ID: 27776337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.